Skip to main content
. 2019 Jul 5;6(8):1383–1394. doi: 10.1002/acn3.50820

Figure 2.

Figure 2

Saturation of CD122 on CD8+ T cells. (A) Representative dot plots of CD122 (Mikβ2 and Mikβ3) and CD8 expressions in CD3+ T lymphocytes of a HAM/TSP patient. (B) Frequencies of Mikβ2+ CD8+ T cells in HAM/TSP patients at pretreatment (pre) and at week 12 of Hu‐Mikβ1 treatment (post). (C) Saturation of Mikβ2+ CD8+ T cells in HAM/TSP patients at week 12 of Hu‐Mikβ1 treatment. Each bar graph represents the mean. (D) Change of frequencies of Mikβ2+ CD8+ T cells in HAM/TSP patients (HAM#1, #5, #6, and #8; left graph, HAM#2, #3, #4, #7, and #9; right graph) during Hu‐Mikβ1 trial. Arrows indicate Hu‐Mikβ1 dosing. (E) Tax11‐19‐ and CMV pp65‐specific CD8+ T cells in a HAM/TSP patient during Hu‐Mikβ1 trial. Representative dot plots of Tax11‐19‐ and CMV pp65‐tetramer staining in CD3+ lymphocytes of a HAM/TSP patient. (F) Frequencies of Tax11‐19‐ and CMV pp65‐specific CD8+ T cells in a HAM/TSP patient during Hu‐Mikβ1 trial. Arrows indicate Hu‐Mikβ1 dosing